Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 1
2010 1
2014 1
2015 1
2016 1
2017 1
2020 2
2023 1
2024 1
2025 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.
Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Kaffenberger BH, Lunning M, McGettigan S, McPherson J, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Pennell N, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Weight RM, Johnson-Chilla A, Zuccarino-Catania G, Engh A. Thompson JA, et al. Among authors: weight rm. J Natl Compr Canc Netw. 2020 Mar;18(3):230-241. doi: 10.6004/jnccn.2020.0012. J Natl Compr Canc Netw. 2020. PMID: 32135517
Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways.
Lacouture ME, Goleva E, Shah N, Rotemberg V, Kraehenbuehl L, Ketosugbo KF, Merghoub T, Maier T, Bang A, Gu S, Salvador T, Moy AP, Lyubchenko T, Xiao O, Hall CF, Berdyshev E, Crooks J, Weight R, Kern JA, Leung DYM. Lacouture ME, et al. Among authors: weight r. Clin Cancer Res. 2024 Jul 1;30(13):2822-2834. doi: 10.1158/1078-0432.CCR-23-3431. Clin Cancer Res. 2024. PMID: 38652814 Free PMC article.
IL12/23 Blockade for Refractory Immune-Mediated Colitis: 2-Center Experience.
Shirwaikar Thomas A, Lee SE, Shatila M, De Toni EN, Török HP, Ben Khaled N, Powell N, Weight R, Faleck DM, Wang Y. Shirwaikar Thomas A, et al. Among authors: weight r. Am J Gastroenterol. 2023 Sep 1;118(9):1679-1683. doi: 10.14309/ajg.0000000000002332. Epub 2023 Jun 22. Am J Gastroenterol. 2023. PMID: 37216614 Free PMC article.
Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors.
Milhem MM, Wise-Draper TM, Chandra S, Hanna GJ, Laux DE, Medina TM, Ansstas G, Daud A, Kelly CM, O'Day SJ, Perez CA, Wong MK, Friedlander PA, Kristedja TS, Burgess MA, Cowey CL, Hanks BA, Weight RM, Daniel WL, Feltner DE, Mix S, Sindelar L, Bexon AS, Bexon MF, Michel RE, Bhatia S. Milhem MM, et al. Among authors: weight rm. J Immunother Cancer. 2025 Jul 25;13(7):e011651. doi: 10.1136/jitc-2025-011651. J Immunother Cancer. 2025. PMID: 40713179 Free PMC article. Clinical Trial.
13 results